Year-over-year net earnings per share growth for the last 12 months: Regulus (RGLS)
The development of miRNA therapy for the treatment of polycystic kidney disease by Regulus Therapeutics (RGLS) depends directly on the upcoming results of Phase 2 trials, as confirmed by the quarterly EPS percentage change in the intraday price action on the GURU.Markets chart, where the indicator value reaches 50.20. The market has already priced in current liquidity following the issuance. In the future, the success of unique genetic products will provide the company with monopoly pricing power.
Analytical breakdowns for Regulus Therapeutics
- market value and analyst target forecast:
- company stock exchange capitalization indicators:
- book capitalization indicators:
- business debt structure and liquidity details:
Total Debt to Capital Regulus Therapeutics|RGLS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Regulus Therapeutics|RGLS - Aggregate Debt Obligations|Debts to Book Capitalization Regulus Therapeutics Inc|RGLS - Company Long-Term Debts|Company Short-Term Debt Regulus Therapeutics|Quick Ratio regulusrx.com
- earnings and valuation multiples information:
RGLS - Company Net Income|Future Profit Regulus Therapeutics|RGLS - P/E Multiple|Projected Price to Earnings Regulus Therapeutics Inc|RGLS - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Regulus Therapeutics Inc|RGLS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Regulus Therapeutics|RGLS - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months regulusrx.com|RGLS - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Regulus Therapeutics
Summary company analytics:Regulus Therapeutics Inc. - RGLS
Quarterly EPS growth measures the dynamics of net income per share, reflecting capital management efficiency and business scaling rates. By analyzing the history of quarterly EPS changes, an investor assesses the operational momentum of Regulus Therapeutics (RGLS), where the commercialization potential of drugs for polycystic kidney disease and patent protection create the foundation for a transition toward stable free cash flow generation.
Competitor analysis
Tempus AI Inc (TEM) - Year-over-year earnings per share growth for the last twelve months|QGEN - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months IONS|RGEN: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months RNA (Avidity Biosciences)|Year-over-year earnings per share growth rate for the last twelve months CRSP|Quarterly EPS earnings growth WGS (GeneDx)|Year-over-year earnings per one share growth for the last 12 months RARE|Beam Therapeutics Corp - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Sarepta Corp|Twist Bioscience (TWST) - Year-over-year earnings per share growth for the last twelve months|10xgenomics.com - Year-over-year earnings per one share growth for the last 12 months|NTLA (Intellia Therapeutics, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Stoke Therapeutics Inc|Year-over-year earnings per share growth for the last twelve months BioLife Corp (BLFS)|WVE: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth MAZE (Maze Therapeutics Inc)|sionnatx.com (SION) - Earnings per share growth in annualized terms for the last twelve months|PRME: Year-over-year net earnings per share growth for the last 12 months|TSHA - Quarterly EPS earnings growth|QURE (uniQure Corp) - Year-over-year net earnings per share growth for the last 12 months|MGTX: Year-over-year earnings per share growth rate for the last twelve months|RGNX (REGENXBIO Inc.) - Quarterly EPS earnings growth|solidbio.com (SLDB) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth OCGN|Year-over-year net earnings per share growth for the last 12 months Pacific Biosciences of California, Inc. PACB|Year-over-year earnings per share growth for the last twelve months Benitec BNTC|Year-over-year net earnings per share change for the last twelve months Design Corp (DSGN)|RCKT - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months FDMT (4dmoleculartherapeutics.com)|LXEO: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Korro Bio KRRO|Year-over-year earnings per share growth for the last twelve months Editas|Year-over-year earnings per share growth for the last twelve months SLN|Year-over-year earnings per share growth for the last twelve months ProQR Therapeutics N.V. (PRQR)|Year-over-year net earnings per share change for the last twelve months codexis.com|Quarterly EPS earnings growth SGMO (Sangamo Therapeutics, Inc.)|NAUT: Year-over-year earnings per share growth for the last 12 months|MGX - Year-over-year earnings per share growth for the last twelve months|DTIL (precisionbiosciences.com) - Year-over-year earnings per share growth for the last 12 months|GBIO: Quarterly EPS earnings growth|boundlessbio.com (BOLD) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Exicure Inc.|IMNN: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth PHIO|MBIO - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth RNAZ (TransCode Therapeutics, Inc.)|Net earnings per share growth for the trailing year Bionano Genomics Inc.|APDN: Year-over-year net earnings per share growth for the last 12 months|BLUE - Quarterly EPS earnings growth|immunoprecise.com (IPA) - Year-over-year earnings per share growth for the last twelve months|OMGA (Omega Therapeutics Corp) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OMIC|Quarterly EPS earnings growth syros.com|Year-over-year earnings per share growth for the last twelve months Telesis Bio (TBIO)|Year-over-year net earnings per share change for the last twelve months TRACON Pharmaceuticals Inc.|Unity Bio - Year-over-year net earnings per share growth for the last 12 months
